NAPNAP's Developmental-Behavioral & Mental Health SIG
We warmly welcome you to our SIG's collaborative resource site!
Please refer to our Terms of Use and Privacy Policy prior to accessing the site.
  • DBMH Resource
  • Topics
    • ADHD
    • Anxiety >
      • Agoraphobia
      • Generalized Anxiety Disorder
      • Illness Anxiety Disorder
      • Selective Mutism
      • Separation Anxiety Disorder
      • Social Phobia Disorder
      • Specific Phobia
    • ASD
    • Bipolar
    • Cerebral Palsy
    • Cleft Lip or Palette
    • Communication Disorders
    • Depressive Disorders
    • Development >
      • Normal Development
      • Cognition, Social
      • Gross Motor
      • Speech, Language
    • Disruptive, Impulse-Control, and Conduct Disorders
    • Dissociative Identity Disorder
    • Eating & feeding disorders
    • Elimination Disorders >
      • Enuresis
      • Encopresis
    • Fetal Alcohol Spectrum Disorders
    • Gender Dysphoria
    • Genetic Disorders >
      • Down syndrome
      • DiGeorge
      • Fragile X
      • Klinefelter
      • Inborn errors of metabolism
      • Marfan
      • Mitochondrial
      • Lysosomal
      • Prader-Willi
      • Rett syndrome
      • Rubinstein-Taybi
      • Tay-Sachs
      • Turner syndrome
      • Williams syndrome
    • Habit Disorders
    • Intellectual Disabilities
    • Language Disorders
    • Learning Disabilities
    • OCD and Related
    • Schizophrenia Spectrum
    • Sensory Integration
    • Somatic Symptoms
    • Spina Bifida
    • Substance Use
    • Trauma or Stress-Related
  • By Age
    • Neonate-Infant
    • Toddler
    • School-Age
    • Adolescent
  • PC Integration
  • Training
  • Resources
  • Calendar

Agoraphobia

Agoraphobia is an anxiety disorder that is characterized by extreme fear of places or situations that cause panic, embarrassment, or helplessness. Those with agoraphobia can experience symptoms that greatly limit activities of daily living. Agoraphobia may occur with or without Panic Disorder. Treatment includes: Cognitive-behavioral and other psychotherapies and medication.

Symptoms include fear of the following:
  • Leaving home, especially alone
  • Waiting in line
  • Using public transportation
  • Crowds
  • Enclosed or open spaces

DSM-V Criteria:
A marked fear or anxiety about two (or more) of the following five situations:
  • Using public transportation
  • Being in open spaces
  • Being in enclosed spaces (e.g., shops, theaters, cinemas)
  • Standing in line or being in a crowd
  • Being outside the home alone.
The situations are avoided (e.g., travel is restricted) or else are endured with marked distress or with anxiety about having a panic attack or panic-like symptoms, or require the presence of a companion.

The agoraphobic situations almost always provoke fear or anxiety.

The fear or anxiety is out of proportion to the actual danger posed by the agoraphobic situations and to the sociocultural context.
The fear, anxiety, or avoidance is persistent, typically lasting 6 months or more.
The fear, anxiety, or avoidance causes clinically significant distress or impairment in important areas of functioning.

Common Comorbidities:
  • Panic disorder
  • Major Depressive Disorder
  • Social Phobia
  • Generalized Anxiety Disorder
  • Obsessive-compulsive Disorder
  • Substance Use Disorders

Screening & Assessment

  • Severity Measure for Agoraphobia, Child Age 11 to 17 (APA Emerging Measures)

Position Papers & Practice Parameters

  • AACAP's Practice Parameter for the Assessment and Treatment of Children and Adolescents with Anxiety Disorders (2007)

Articles

  • Clinical Consequences of the Revised DSM-V Definition of Agoraphobia in Treatment-Seeking Anxious Youth (Cornacchio, Chou, Sacks, Pincus & Comer, 2017)

Resources

  • Agoraphobia in Children (Child Mind Institute)

Organizations

  • Anxiety and Depression Association of America (ADAA)
  • Agoraphobia and Panic Disorder Association (APD)

Content curated by Linzy Silberg, BSN, RN.
Please refer to our Terms of Use  and Privacy Policy prior to accessing the site.
DISCLAIMER: NAPNAP's DBMH SIG site is for informational and educational purposes only. All informational materials and guides on this site are offered "as is" and are NOT a substitute for medical advice, diagnostic analysis, or treatment planning by a licensed provider. Please note that the information found on this site is not a comprehensive review of any condition, drug, or body system; do not use it to replace clinical decision making. By accessing this resource, you agree that neither NAPNAP nor its SIG group editors will be legally held responsible for any clinical, professional or personal actions taken as a result of using this site.
Proudly powered by Weebly